Cardinal Health (CAH)
(Delayed Data from NYSE)
$93.74 USD
-0.36 (-0.38%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $93.76 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.74 USD
-0.36 (-0.38%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $93.76 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
US States Get $26B Settlement Deal in Opioid Abuse Litigation
by Indrajit Bandyopadhyay
Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may join the deal soon.
Cardinal Health (CAH) Introduces 2 New Digital Solutions
by Zacks Equity Research
Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.
Cardinal Health's (CAH) Arm Receives FDA Nod for LYMPHOSEEK
by Zacks Equity Research
Cardinal Health's (CAH) Nuclear & Precision Health Solutions receive FDA approval for LYMPHOSEEK injection.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, segmental weakness is a woe.
PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.
Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.
Cardinal Health (CAH) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -3.16% and -1.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results are likely to reflect solid performance in Pharmaceutical segment.
Cardinal Health (CAH), HHS Partner to Offer Pandemic Support
by Zacks Equity Research
The contract should help Cardinal Health (CAH) provide critical pandemic support in partnership with the U.S. government.
Why Cardinal (CAH) Could Beat Earnings Estimates Again
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
Cardinal Health (CAH) Unveils Navista TS to Boost Patient Care
by Zacks Equity Research
Cardinal Health (CAH) Specialty Solutions' newly launched Navista TS will help community oncologists to improve patient care and become successful in value-based care while reducing costs.
Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator
by Zacks Equity Research
Ecolab's (ECL) smart tool is expected to bridge the widening gap between freshwater supply and demand via efficient water management.
AmerisourceBergen (ABC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AmerisourceBergen (ABC) is optimistic about maintaining a robust segmental performance amid the pandemic-led business disruptions.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Cardinal Health, Abbott Lab, Hologic and Bio-Rad Lab
Cardinal Health (CAH) Hits New 52-week High: What's Driving It?
by Zacks Equity Research
Cardinal Health (CAH) is witnessing an uptrend in its stock price, prompted by robust performance in both Pharmaceutical and Medical segments during the fiscal second quarter.
MedTech to Gain From Economic Stimulus Bill: 3 Stocks to Buy
by Trina Mukherjee
Grab these three top stocks - ABT, HOLX and BIO - that continue to show tremendous promise and stand to benefit from the historic stimulus package.
Cardinal Health (CAH) Inks Deal to Divest Cordis Business
by Zacks Equity Research
Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
by Zacks Equity Research
Zacks Industry Outlook Highlights: McKesson Corp, West Pharmaceutical Services, Cardinal Health, Align Technology and Dentsply Sirona
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results reflect strong segmental performance.